Key Drivers
- Strong liquidity
- Zero revenue
- Heavy losses
AIAI Summary
TRVI has shifted from a financing-risk biotech to a late-stage, cash-backed catalyst story, but the stock now hinges almost entirely on flawless Phase 3 execution for Haduvio—so the key trade is owning the upside into OCEAN-1/OCEAN-2 while watching for any delay, efficacy miss, or loss of the $17.50 support level.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •Heavy losses
TRVI has a very strong, low-leverage cash position, but zero revenue, ongoing losses, and a rich 8.2x price-to-book make the stock look fundamentally challenged despite ample liquidity. #loss-making
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Stalled breakout
- •Holding support
Over the last month, TRVI has recovered from a sharp drop into a modest higher-low uptrend, but it remains range-bound below $18.75-$19.07 and needs to hold $17.50 to keep the rebound intact.
Sharp mid-July drop from $16.77, followed by a gradual rebound to $18.46
Sentiment & News
Key News Insights:
- •Phase 3 start
- •Pipeline expansion
- •Investor outreach
Trevi Therapeutics advanced Haduvio with a Phase 3 OCEAN-1 trial start and plans for OCEAN-2, signaling steady late-stage progress in chronic cough.
This update is modestly positive for TRVI as continued late-stage trial execution supports Haduvio's development momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings